Motif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life threatening infections caused by multi drug resistant bacteria.
Quote | Motif Bio plc (NASDAQ:MTFB)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.105011 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 01/21/2020 04:28:28 pm |
News | Motif Bio plc (NASDAQ:MTFB)
Motif Bio (NASDAQ: MTFB ) intends to voluntarily delist its American Depository Shares (ADSs) and listed warrants from the Nasdaq Capital Market. More news on: Motif Bio plc, Healthcare stocks news, Read more ...
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company") announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares (ADSs)...
Message Board Posts | Motif Bio plc (NASDAQ:MTFB)
Subject | By | Source | When |
---|---|---|---|
Clinton_j: JORDAN FOREX | Clinton_j | investorshangout | 01/13/2020 8:24:36 AM |
Dont know it yet ? Not sure | wedman | investorshub | 12/23/2019 4:31:17 PM |
What is the New stock symbol now for | Value_Investor | investorshub | 12/23/2019 4:29:19 PM |
Yes I still own. Missed my opportunity to | wedman | investorshub | 12/23/2019 4:23:40 PM |
Do you still own any shares now? If | Value_Investor | investorshub | 12/21/2019 7:32:20 PM |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company") announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares (ADSs)...
NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will be utilising NIAID’s 1 suite of preclinical services through JMI Laboratories ...
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its Lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreemen...